Person: Kolossa-Gehring, Marike
Lade...
E-Mail-Adresse
Geburtsdatum
Forschungsvorhaben
Organisationseinheiten
Berufsbeschreibung
Biologin
Toxikologin
Toxikologin
Nachname
Kolossa-Gehring
Vorname
Marike
Name
3 Ergebnisse
Suchergebnisse
Gerade angezeigt 1 - 3 von 3
Veröffentlichung Human-Biomonitoring für Europa (HBM4EU) - erste Einblicke in die Ergebnisse der Initiative(2022) Apel, Petra; Kolossa-Gehring, Marike; Weise, PhilippBeim Human-Biomonitoring wird die innere Schadstoffbelastung des Menschen aus verschiedenen Quellen wie Nahrung, Alltagsgegenständen oder Atemluft erfasst, indem z.B. Blut und Urin analysiert werden. Um das Human-Biomonitoring in Europa zu fördern und zu koordinieren, wurde 2017 das Projekt "Human-Biomonitoring für Europa" (HBM4EU) begonnen, an dem sich 30 Länder, die Europäische Umweltagentur und die Europäische Kommission beteiligt haben. Im Juni 2022 wurde das Projekt abgeschlossen. Vergleichbare und zuverlässige Belastungsdaten konnten für eine breite Palette von Umweltchemikalien erfasst und einheitlich bewertet werden. Weitere wichtige Erfolge der Initiative waren die Etablierung eines Kontrollprogramms zur Qualitätssicherung, ein Konzept zur Vereinheitlichung zukünftiger HBM-Studien, eine gemeinsame Strategie zur Ableitung von gesundheitsbezogenen Beurteilungswerten (HBM Guidance Values - HBM-GVs) und die Einrichtung nationaler Gremien. Die gewonnenen Belastungsdaten sind über die Informationsplattform für die Überwachung von Chemikalien (IPCHEM) und das EU HBM-Dashboard zugänglich. Publikationen sind über die HBM4EU-Onlinebibliothek frei verfügbar. Insgesamt zeigen die Ergebnisse, dass die Belastungen der EU-Bevölkerung für viele Chemikalien wie etwa Phthalate und perfluorierte Alkylsubstanzen (PFAS) zu hoch sind und weiterhin Handlungsbedarf seitens der Politik besteht. Das im Projekt HBM4EU generierte Wissen kann die politischen Entscheidungsträger:innen bei der Verbesserung der Chemikalienââą Ì, Umwelt- und Gesundheitspolitik unterstützen. © Der/die Autor(en) 2022Veröffentlichung Phthalate metabolites in 24-h urine samples of the German Environmental Specimen Bank (ESB) from 1988 to 2015 and a comparison with US NHANES data from 1999 to 2012(2017) Koch, Holger M.; Apel, Petra; Schütze, Andre; Conrad, André; Pälmke, Claudia; Kolossa-Gehring, Marike; Brüning, Thomas; Rüther, MariaThe German Environmental Specimen Bank (ESB) continuously collects 24-h urine samples since theearly 1980s in Germany. In this study we analyzed 300 urine samples from the years 2007 to 2015 for 21phthalate metabolites (representing exposure to 11 parent phthalates) and combined the data with twoprevious retrospective measurement campaigns (1988 to 2003 and 2002 to 2008). The combined datasetcomprised 1162 24-h urine samples spanning the years 1988 to 2015. With this detailed set of humanbiomonitoring data we describe the time course of phthalate exposure in Germany over a time frame of27 years. For the metabolites of the endocrine disrupting phthalates di(2-ethylhexyl) phthalate (DEHP),di-n-butyl phthalate (DnBP) and butylbenzyl phthalate (BBzP) we observed a roughly ten-fold decline inmedian metabolite levels from their peak levels in the late 1980s/early 1990s compared to most recentlevels from 2015. Probably, bans (first enacted in 1999) and classifications/labelings (enacted in 2001 and2004) in the European Union lead to this drop. A decline in di-isobutyl phthalate (DiBP) metabolite levelsset in only quite recently, possibly due to its later classification as a reproductive toxicant in the EU in 2009.In a considerable number of samples collected before 2002 health based guidance values (BE, HBM I) havebeen exceeded for DnBP (27.2%) and DEHP (2.3%) but also in recent samples some individual exceedancescan still be observed (DEHP 1.0%). A decrease in concentration for all low molecular weight phthalates,labelled or not, was seen in the most recent years of sampling. For the high molecular weight phthalates,DEHP seems to have been substituted in part by di-isononyl phthalate (DiNP), but DiNP metabolite levelshave also been declining in the last years. Probably, non-phthalate alternatives increasingly take overfor the phthalates in Germany. A comparison with NHANES (National Health and Nutrition ExaminationSurvey) data from the United States covering the years 1999 to 2012 revealed both similarities anddifferences in phthalate exposure between Germany and the US. Exposure to critical phthalates hasdecreased in both countries with metabolite levels more and more aligning with each other, but highmolecular weight phthalates substituting DEHP (such as DiNP) seem to become more important in theUS than in Germany.
© 2016 Elsevier GmbH. All rights reservedVeröffentlichung The European Human Biomonitoring Initiative (HBM4EU): Human biomonitoring guidance values for selected phthalates and a substitute plasticizer(2021) Apel, Petra; Kolossa-Gehring, Marike; Rousselle, Christophe; Lange, RosaUbiquitous use of plasticizers has led to a widespread internal exposure of the European population. Until today, metabolites are detected in almost every urine sample analysed. This raised the urgent need for a toxicological interpretation of the internal exposure levels. The European Human Biomonitoring Initiative (HBM4EU) contributes substantially to the knowledge on the actual exposure of European citizens to chemicals prioritised within HBM4EU, on their potential impact on health and on the interpretation of these data to improve policy making. On that account, human biomonitoring guidance values (HBM-GVs) are derived for the general population and the occupationally exposed population agreed at HBM4EU consortium level. These values can be used to assess phthalate exposure levels measured in HBM studies in a health risk assessment context. HBM-GVs were derived for five phthalates (DEHP, DnBP, DiBP, BBzP and DPHP) and for the non-phthalate substitute Hexamoll® DINCH. For the adult general population, the HBM-GVs for the specific metabolite(s) of the respective parent compounds in urine are the following: 0.5 mg/L for the sum of 5-oxo-MEHP and 5-OH-MEHP; 0.19 mg/L for MnBP, 0.23 mg/L for MiBP; 3 mg/L for MBzP; 0.5 mg/L for the sum of oxo-MPHP and OH-MPHP and 4.5 mg/L for the sum of OH-MINCH and cx-MINCH. The present paper further specifies HBM-GVs for children and for workers. Quelle: © 2021 The Author(s)